First in human study to evaluate AZD9793 in participants with advanced or metastatic solid tumours

Trial Identifier: D7040C00001
Sponsor: AstraZeneca
Start Date: March 2025
Primary Completion Date: February 2028
Study Completion Date: July 2028
Condition: Liver Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Chengdu, CN, 610041
CN Guangzhou, CN, 510515
CN Harbin, CN, 150049
CN Shanghai, CN, 201114
ES Barcelona, ES, 8035
ES Pamplona, ES, 31008
HK Pokfulam, HK, 999077
HK Shatin, HK, 000000
JP Kashiwa, JP, 277-8577
JP Yokohama-shi, JP, 241-8515
KR Seoul, KR, 06351
KR Seoul, KR, 5505
TW Taipei, TW, 10002
TW Taoyuan, TW, 333
US, CA La Jolla, CA, US, 92093
US, CA Los Angeles, CA, US, 90089
US, MD Baltimore, MD, US, 21201
US, MO Saint Louis, MO, US, 63108
US, NJ Hackensack, NJ, US, 07601
US, TX Houston, TX, US, 77030